CN1182154C - 新的多拉抑放素衍生物及其制备方法和用途 - Google Patents

新的多拉抑放素衍生物及其制备方法和用途 Download PDF

Info

Publication number
CN1182154C
CN1182154C CNB961944676A CN96194467A CN1182154C CN 1182154 C CN1182154 C CN 1182154C CN B961944676 A CNB961944676 A CN B961944676A CN 96194467 A CN96194467 A CN 96194467A CN 1182154 C CN1182154 C CN 1182154C
Authority
CN
China
Prior art keywords
xaa
val
xab
peptide
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB961944676A
Other languages
English (en)
Chinese (zh)
Other versions
CN1187198A (zh
Inventor
A���Ʋ���
A·浩伯特
F·艾姆林
��Ī������
C·A·罗莫道
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ai Bowei Germany & Co KG GmbH
Original Assignee
BASF SE
Abbott GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE, Abbott GmbH and Co KG filed Critical BASF SE
Publication of CN1187198A publication Critical patent/CN1187198A/zh
Application granted granted Critical
Publication of CN1182154C publication Critical patent/CN1182154C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CNB961944676A 1995-06-07 1996-06-03 新的多拉抑放素衍生物及其制备方法和用途 Expired - Fee Related CN1182154C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/472,453 1995-06-07
US08/472,453 US5831002A (en) 1992-05-20 1995-06-07 Antitumor peptides

Publications (2)

Publication Number Publication Date
CN1187198A CN1187198A (zh) 1998-07-08
CN1182154C true CN1182154C (zh) 2004-12-29

Family

ID=23875567

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB961944676A Expired - Fee Related CN1182154C (zh) 1995-06-07 1996-06-03 新的多拉抑放素衍生物及其制备方法和用途
CNB961944684A Expired - Fee Related CN1182153C (zh) 1995-06-07 1996-06-03 新的多拉抑放素衍生物及其制备方法和用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB961944684A Expired - Fee Related CN1182153C (zh) 1995-06-07 1996-06-03 新的多拉抑放素衍生物及其制备方法和用途

Country Status (33)

Country Link
US (1) US5831002A (cs)
EP (2) EP0871656B1 (cs)
JP (2) JP4221062B2 (cs)
KR (2) KR100437985B1 (cs)
CN (2) CN1182154C (cs)
AR (2) AR003136A1 (cs)
AT (2) ATE224910T1 (cs)
AU (2) AU725164B2 (cs)
BG (2) BG102125A (cs)
BR (2) BR9609423A (cs)
CA (2) CA2219819C (cs)
CO (2) CO4700527A1 (cs)
CZ (2) CZ293682B6 (cs)
DE (2) DE69623472T2 (cs)
DK (2) DK0871656T3 (cs)
ES (2) ES2188759T3 (cs)
HR (2) HRP960257A2 (cs)
HU (2) HU228071B1 (cs)
IL (2) IL122215A (cs)
MX (2) MX9709146A (cs)
MY (2) MY119042A (cs)
NO (2) NO318384B1 (cs)
NZ (2) NZ310443A (cs)
PL (2) PL185762B1 (cs)
PT (2) PT832104E (cs)
RO (2) RO118953B1 (cs)
SI (2) SI0871656T1 (cs)
SK (1) SK282466B6 (cs)
TR (2) TR199701545T1 (cs)
TW (2) TW508357B (cs)
UA (2) UA46776C2 (cs)
WO (2) WO1996040751A1 (cs)
ZA (2) ZA964711B (cs)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
US20010009901A1 (en) * 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
US5965537A (en) * 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US6103698A (en) 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
WO2000051998A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
WO2002088298A1 (en) 2001-04-27 2002-11-07 The Procter & Gamble Company Compounds, compositions, and methods for controlling biofilms
AU2002359792A1 (en) * 2001-12-18 2003-06-30 Proteologics, Inc. Methods and compositions for the inhibition of viral release
AU2003224644A1 (en) * 2002-02-27 2003-09-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Healtan Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
WO2006013552A2 (en) 2004-08-02 2006-02-09 Ramot At Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
CA2619568A1 (en) * 2005-08-19 2007-03-01 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
EP1973928A2 (en) * 2005-10-11 2008-10-01 Ramot at Tel-Aviv University Ltd. Self-assembled fmoc-ff hydrogels
SG10201407457UA (en) 2006-05-16 2014-12-30 Pharmascience Inc Iap bir domain binding compounds
JP5452223B2 (ja) * 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ阻害剤
CA2683098C (en) * 2007-04-12 2014-03-18 Scinopharm Taiwan Ltd. Process for making galantamine
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
MX340870B (es) 2010-02-12 2016-07-27 Pharmascience Inc Compuestos de unión del dominio de repetición de inhibidores de proteínas de apoptosis de baculovirus.
WO2012092411A2 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc. Phenanthridine macrocyclic hepatitis c serine protease inhibitors
CN103534256B (zh) 2010-12-30 2016-08-10 益安药业 大环丙型肝炎丝氨酸蛋白酶抑制剂
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CN103717595A (zh) 2011-05-27 2014-04-09 Ambrx公司 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
EP4400121A1 (en) 2021-09-03 2024-07-17 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
SG87056A1 (en) * 1991-08-09 2002-03-19 Teikoku Hormone Mfg Co Ltd Novel tetrapeptide derivative
DE69320339T2 (de) * 1992-05-20 1998-12-17 Basf Ag, 67063 Ludwigshafen Derivate des Dolastatin
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides

Also Published As

Publication number Publication date
SK282466B6 (sk) 2002-02-05
HUP9801817A2 (hu) 1998-11-30
BG102152A (en) 1998-09-30
HU228073B1 (hu) 2012-09-28
IL122216A0 (en) 1998-04-05
CA2219819A1 (en) 1996-12-19
KR100437985B1 (ko) 2004-09-18
BR9609424A (pt) 2000-03-28
BR9609423A (pt) 1999-06-29
HUP9801910A2 (hu) 1999-01-28
CN1187198A (zh) 1998-07-08
DE69623472T2 (de) 2003-08-21
SI0871656T1 (en) 2003-08-31
MX9709147A (es) 1998-03-31
HUP9801910A3 (en) 1999-06-28
IL122216A (en) 2002-02-10
SI0832104T1 (en) 2003-08-31
DE69623992T2 (de) 2003-05-22
HRP960257A2 (en) 1998-02-28
HUP9801817A3 (en) 1999-06-28
JPH11504653A (ja) 1999-04-27
MX9709146A (es) 1998-03-31
ATE224910T1 (de) 2002-10-15
CA2219818A1 (en) 1996-12-19
IL122215A (en) 2001-08-26
RO119783B1 (ro) 2005-03-30
KR100437986B1 (ko) 2004-09-18
JP3957751B2 (ja) 2007-08-15
JP4221062B2 (ja) 2009-02-12
AU6124296A (en) 1996-12-30
TR199701544T1 (xx) 1998-03-21
CZ376397A3 (cs) 1998-06-17
PL323726A1 (en) 1998-04-14
CZ293683B6 (cs) 2004-07-14
PL185763B1 (pl) 2003-07-31
CA2219818C (en) 2008-05-20
DE69623472D1 (de) 2002-10-10
NO975710L (no) 1998-02-02
UA46775C2 (uk) 2002-06-17
PL185762B1 (pl) 2003-07-31
SK165397A3 (en) 1998-10-07
UA46776C2 (uk) 2002-06-17
MY119042A (en) 2005-03-31
WO1996040751A1 (en) 1996-12-19
WO1996040752A1 (en) 1996-12-19
NO318384B1 (no) 2005-03-14
HU228071B1 (hu) 2012-09-28
EP0871656B1 (en) 2002-09-25
CA2219819C (en) 2008-05-20
EP0871656A1 (en) 1998-10-21
TR199701545T1 (xx) 1998-04-21
CZ293682B6 (cs) 2004-07-14
DK0832104T3 (da) 2003-01-06
ZA964711B (en) 1997-12-08
ATE223431T1 (de) 2002-09-15
AR003427A1 (es) 1998-08-05
CO4700527A1 (es) 1998-12-29
AU6124196A (en) 1996-12-30
ES2188759T3 (es) 2003-07-01
AU725164B2 (en) 2000-10-05
CN1187199A (zh) 1998-07-08
NZ310444A (en) 1999-11-29
AU725170B2 (en) 2000-10-05
NO317670B1 (no) 2004-11-29
TW508357B (en) 2002-11-01
US5831002A (en) 1998-11-03
ES2186783T3 (es) 2003-05-16
AR003136A1 (es) 1998-07-08
KR19990022582A (ko) 1999-03-25
DE69623992D1 (de) 2002-10-31
NO975710D0 (no) 1997-12-05
PL323723A1 (en) 1998-04-14
KR19990022583A (ko) 1999-03-25
TW424096B (en) 2001-03-01
JPH11504652A (ja) 1999-04-27
HRP960277A2 (en) 1997-10-31
IL122215A0 (en) 1998-04-05
BG102125A (en) 1998-09-30
CZ376597A3 (cs) 1998-06-17
PT871656E (pt) 2002-12-31
RO118953B1 (ro) 2004-01-30
CN1182153C (zh) 2004-12-29
NZ310443A (en) 1999-10-28
PT832104E (pt) 2002-12-31
MY124487A (en) 2006-06-30
NO975711D0 (no) 1997-12-05
EP0832104A1 (en) 1998-04-01
DK0871656T3 (da) 2003-01-27
EP0832104B1 (en) 2002-09-04
CO4700526A1 (es) 1998-12-29
ZA964710B (en) 1997-12-08
NO975711L (no) 1998-01-30

Similar Documents

Publication Publication Date Title
CN1182153C (zh) 新的多拉抑放素衍生物及其制备方法和用途
CN1057095C (zh) 新型肽,其制备及应用
CN1268636C (zh) 多拉司他汀15衍生物
CN1055700C (zh) 治疗用肽衍生物
CN1052731C (zh) 具有生长激素释放特性的化合物
CN1213058C (zh) Fap活化的抗肿瘤化合物
CN86101850A (zh) N，n′-二烷基胍基二肽的制造方法与用途
HK1041007A1 (zh) 截尾海兔肽15衍生物
CN1037711A (zh) 具有t细胞辅助活性的肽类
CN87101164A (zh) 次膦酸衍生物
CN1373669A (zh) 增强了药动学性质的杂合多肽
CN1098409A (zh) α-哌嗪酮及其应用
CN1238781A (zh) 七肽催产素类似物
CN1065874C (zh) 新的肽及其制备和应用
CN1054857C (zh) 具有胃肠道运动刺激活性的胃动素样多肽
CN1157223C (zh) 多拉司他汀-15衍生物与紫杉烷的组合
CN1077960A (zh) 血调节肽
CN1278734A (zh) 用于治疗类风湿性关节炎的方法和组合物
CN1592752A (zh) 用于治疗癌症的e2f－1/细胞周期蛋白相互作用的抑制剂
CN1127514C (zh) 抗癌的肽类
CN1041366A (zh) 具有t细胞抑制基因活性的肽的合成方法
CN1133563A (zh) 在免疫和中枢神经系统(cns)治疗中有用的新的三肽
CN1262561C (zh) 干扰细胞内信号发生的合成多肽
CN1206423A (zh) Dolastatin15的肽衍生物及其用途
CN1068334A (zh) 适用于调节免疫系统及神经系统的肽

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: ABBVIE GERMANY GMBH + CO., KG.

Free format text: FORMER OWNER: EBERT GMBH + CO. KG

Effective date: 20140401

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20140401

Address after: Wiesbaden

Patentee after: Ai Bowei Germany GmbH & Co Kg

Address before: Wiesbaden

Patentee before: Ebert GmbH & Co. KG

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20041229

Termination date: 20150603

EXPY Termination of patent right or utility model